Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $5.00 at HC Wainwright

Key Points

• HC Wainwright raised Kodiak Sciences' price target from $3.00 to $5.00, maintaining a "neutral" rating despite suggesting a potential downside of 52.70% from the current price.
• Other analysts, including JPMorgan Chase & Co. and Barclays, have also changed their ratings, with JPMorgan increasing their target to $15.00 and Barclays raising theirs to $7.00.
• Kodiak Sciences, focused on retinal disease treatments, reported a quarterly loss of ($1.03) earnings per share, missing analyst estimates by $0.02.

Kodiak Sciences (NASDAQ:KOD - Free Report) had its price target upped by HC Wainwright from $3.00 to $5.00 in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a neutral rating on the stock. HC Wainwright also issued estimates for Kodiak Sciences' Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($4.21) EPS, FY2026 earnings at ($4.45) EPS, FY2027 earnings at ($4.40) EPS, FY2028 earnings at ($3.42) EPS and FY2029 earnings at ($1.87) EPS.

KOD has been the subject of a number of other research reports. JPMorgan Chase & Co. upgraded Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price objective for the company in a research note on Thursday, August 14th. Barclays lifted their price objective on Kodiak Sciences from $4.00 to $7.00 and gave the company an "underweight" rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $11.75.

Kodiak Sciences Stock Performance

Shares of KOD traded up $0.49 on Monday, reaching $10.20. The stock had a trading volume of 669,916 shares, compared to its average volume of 704,460. The firm has a market capitalization of $538.78 million, a price-to-earnings ratio of -2.68 and a beta of 2.41. The company has a 50-day simple moving average of $6.18 and a 200-day simple moving average of $4.57. Kodiak Sciences has a 12-month low of $1.92 and a 12-month high of $11.60.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.02). On average, analysts expect that Kodiak Sciences will post -3.45 EPS for the current fiscal year.

Institutional Trading of Kodiak Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. US Bancorp DE increased its holdings in shares of Kodiak Sciences by 131.7% in the 1st quarter. US Bancorp DE now owns 9,282 shares of the company's stock worth $26,000 after purchasing an additional 5,276 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Kodiak Sciences in the first quarter worth $28,000. Headlands Technologies LLC grew its holdings in shares of Kodiak Sciences by 256.4% in the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after acquiring an additional 5,815 shares during the period. Walleye Capital LLC bought a new stake in shares of Kodiak Sciences in the first quarter worth $49,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Kodiak Sciences by 21.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after acquiring an additional 2,691 shares during the period. Institutional investors own 89.06% of the company's stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.